APO RESEARCH · REPORT
Colloids (Blood Plasma)
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Product & engineering
Understand the product.
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
Selected research
Market Outlook & Growth Opportunities
Global Colloids (Blood Plasma) Market Outlook and Growth Opportunities 2026
Market perspective
Colloids (blood plasma) are the substances of expanding the circulating blood volume, which mainly contain albumin type, gelatin type, dextran type and hydroxyethyl starch type.
Colloids (Blood Plasma) can be applied for extensive burns, massive blood or plasma loss and hypovolemic shock. In this report, we calculate colloids (blood plasma) preparations, which is produced by albumin, gelatin, dextran and hydroxyethyl starch.
North America is the largest Colloids (Blood Plasma) market with about 33% market share. Europe is follower, accounting for about 28% market share.
Read the full market overview
The key players are CSL Behring, Baxter, Grifols, Octapharma, Kedrion, Shanghai Raas, CTBB, Hualan Bio, Rongsheng Pharmaceutical, Boya Rongsheng, B. Braun Medical, Fresenius Kabi, HOSPIRA, Axa parenterals, Fresenius Kabi(China), CR Double-Crane, Kelun Group, Shandong Qidu Pharmaceutical, Shandong Hualu Pharmaceutical, Minsheng Pharma, Kanglepharm etc. Top 3 companies occupied about 46% market share.
This report provides an overview of the global Colloids (Blood Plasma) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Colloids (Blood Plasma) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Colloids (Blood Plasma) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Colloids (Blood Plasma) market size, projected growth trends, production technologies, key applications, and end-use industries.
Colloids (Blood Plasma) Segment by Company
CSL Behring
Baxter
Grifols
Octapharma
Kedrion
Shanghai Raas
CTBB
Hualan Bio
Rongsheng Pharmaceutical
Boya Rongsheng
B. Braun Medical
Fresenius Kabi
HOSPIRA
Axa parenterals
Fresenius Kabi (China)
CR Double-Crane
Kelun Group
Shandong Qidu Pharmaceutical
Shandong Hualu Pharmaceutical
Minsheng Pharma
Kanglepharm
Colloids (Blood Plasma) Segment by Type
Natural Type Colloids (Blood Plasma)
Synthetic Type Colloids (Blood Plasma)
Colloids (Blood Plasma) Segment by Application
Extensive Burns
Massive Blood or Plasma Loss
Hypovolemic Shock
Others
Colloids (Blood Plasma) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Colloids (Blood Plasma) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Colloids (Blood Plasma) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Colloids (Blood Plasma) significant trends, drivers, influence factors in global and regions.
6. To analyze Colloids (Blood Plasma) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colloids (Blood Plasma) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Colloids (Blood Plasma) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colloids (Blood Plasma).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Colloids (Blood Plasma) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Colloids (Blood Plasma) industry.
Chapter 3: Detailed analysis of Colloids (Blood Plasma) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Colloids (Blood Plasma) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Colloids (Blood Plasma) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Natural Type Colloids (Blood Plasma)
- Synthetic Type Colloids (Blood Plasma)
Applications
- Extensive Burns
- Massive Blood or Plasma Loss
- Hypovolemic Shock
- Others
Companies covered
- CSL Behring
- Baxter
- Grifols
- Octapharma
- Kedrion
- Shanghai Raas
- CTBB
- Hualan Bio
- Rongsheng Pharmaceutical
- Boya Rongsheng
- B. Braun Medical
- Fresenius Kabi
- HOSPIRA
- Axa parenterals
- Fresenius Kabi (China)
- CR Double-Crane
- Kelun Group
- Shandong Qidu Pharmaceutical
- Shandong Hualu Pharmaceutical
- Minsheng Pharma
- Kanglepharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Colloids (Blood Plasma) Sales Value (2021-2032)
- 1.2.2 Global Colloids (Blood Plasma) Sales Volume (2021-2032)
- 1.2.3 Global Colloids (Blood Plasma) Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Colloids (Blood Plasma) Market Dynamics
- 2.1 Colloids (Blood Plasma) Industry Trends
- 2.2 Colloids (Blood Plasma) Industry Drivers
- 2.3 Colloids (Blood Plasma) Industry Opportunities and Challenges
- 2.4 Colloids (Blood Plasma) Industry Restraints
3 Colloids (Blood Plasma) Market by Company
- 3.1 Global Colloids (Blood Plasma) Company Revenue Ranking in 2025
- 3.2 Global Colloids (Blood Plasma) Revenue by Company (2021-2026)
- 3.3 Global Colloids (Blood Plasma) Sales Volume by Company (2021-2026)
- 3.4 Global Colloids (Blood Plasma) Average Price by Company (2021-2026)
- 3.5 Global Colloids (Blood Plasma) Company Ranking (2024-2026)
- 3.6 Global Colloids (Blood Plasma) Company Manufacturing Base and Headquarters
- 3.7 Global Colloids (Blood Plasma) Company Product Type and Application
- 3.8 Global Colloids (Blood Plasma) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Colloids (Blood Plasma) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Colloids (Blood Plasma) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Colloids (Blood Plasma) Market by Type
- 4.1 Colloids (Blood Plasma) Type Introduction
- 4.1.1 Natural Type Colloids (Blood Plasma)
- 4.1.2 Synthetic Type Colloids (Blood Plasma)
- 4.2 Global Colloids (Blood Plasma) Sales Volume by Type
- 4.2.1 Global Colloids (Blood Plasma) Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Colloids (Blood Plasma) Sales Volume by Type (2021-2032)
- 4.2.3 Global Colloids (Blood Plasma) Sales Volume Share by Type (2021-2032)
- 4.3 Global Colloids (Blood Plasma) Sales Value by Type
- 4.3.1 Global Colloids (Blood Plasma) Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Colloids (Blood Plasma) Sales Value by Type (2021-2032)
- 4.3.3 Global Colloids (Blood Plasma) Sales Value Share by Type (2021-2032)
5 Colloids (Blood Plasma) Market by Application
- 5.1 Colloids (Blood Plasma) Application Introduction
- 5.1.1 Extensive Burns
- 5.1.2 Massive Blood or Plasma Loss
- 5.1.3 Hypovolemic Shock
- 5.1.4 Others
- 5.2 Global Colloids (Blood Plasma) Sales Volume by Application
- 5.2.1 Global Colloids (Blood Plasma) Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Colloids (Blood Plasma) Sales Volume by Application (2021-2032)
- 5.2.3 Global Colloids (Blood Plasma) Sales Volume Share by Application (2021-2032)
- 5.3 Global Colloids (Blood Plasma) Sales Value by Application
- 5.3.1 Global Colloids (Blood Plasma) Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Colloids (Blood Plasma) Sales Value by Application (2021-2032)
- 5.3.3 Global Colloids (Blood Plasma) Sales Value Share by Application (2021-2032)
6 Colloids (Blood Plasma) Regional Sales and Value Analysis
- 6.1 Global Colloids (Blood Plasma) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Colloids (Blood Plasma) Sales by Region (2021-2032)
- 6.2.1 Global Colloids (Blood Plasma) Sales by Region: 2021-2026
- 6.2.2 Global Colloids (Blood Plasma) Sales by Region (2027-2032)
- 6.3 Global Colloids (Blood Plasma) Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Colloids (Blood Plasma) Sales Value by Region (2021-2032)
- 6.4.1 Global Colloids (Blood Plasma) Sales Value by Region: 2021-2026
- 6.4.2 Global Colloids (Blood Plasma) Sales Value by Region (2027-2032)
- 6.5 Global Colloids (Blood Plasma) Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Colloids (Blood Plasma) Sales Value (2021-2032)
- 6.6.2 North America Colloids (Blood Plasma) Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Colloids (Blood Plasma) Sales Value (2021-2032)
- 6.7.2 Europe Colloids (Blood Plasma) Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Colloids (Blood Plasma) Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Colloids (Blood Plasma) Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Colloids (Blood Plasma) Sales Value (2021-2032)
- 6.9.2 South America Colloids (Blood Plasma) Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Colloids (Blood Plasma) Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Colloids (Blood Plasma) Sales Value Share by Country, 2025 VS 2032
7 Colloids (Blood Plasma) Country-level Sales and Value Analysis
- 7.1 Global Colloids (Blood Plasma) Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Colloids (Blood Plasma) Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Colloids (Blood Plasma) Sales by Country (2021-2032)
- 7.3.1 Global Colloids (Blood Plasma) Sales by Country (2021-2026)
- 7.3.2 Global Colloids (Blood Plasma) Sales by Country (2027-2032)
- 7.4 Global Colloids (Blood Plasma) Sales Value by Country (2021-2032)
- 7.4.1 Global Colloids (Blood Plasma) Sales Value by Country (2021-2026)
- 7.4.2 Global Colloids (Blood Plasma) Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.9.2 France Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.16.2 China Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.19.2 India Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Colloids (Blood Plasma) Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Colloids (Blood Plasma) Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Colloids (Blood Plasma) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 CSL Behring
- 8.1.1 CSL Behring Company Information
- 8.1.2 CSL Behring Business Overview
- 8.1.3 CSL Behring Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.1.4 CSL Behring Colloids (Blood Plasma) Product Portfolio
- 8.1.5 CSL Behring Recent Developments
- 8.2 Baxter
- 8.2.1 Baxter Company Information
- 8.2.2 Baxter Business Overview
- 8.2.3 Baxter Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Baxter Colloids (Blood Plasma) Product Portfolio
- 8.2.5 Baxter Recent Developments
- 8.3 Grifols
- 8.3.1 Grifols Company Information
- 8.3.2 Grifols Business Overview
- 8.3.3 Grifols Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Grifols Colloids (Blood Plasma) Product Portfolio
- 8.3.5 Grifols Recent Developments
- 8.4 Octapharma
- 8.4.1 Octapharma Company Information
- 8.4.2 Octapharma Business Overview
- 8.4.3 Octapharma Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Octapharma Colloids (Blood Plasma) Product Portfolio
- 8.4.5 Octapharma Recent Developments
- 8.5 Kedrion
- 8.5.1 Kedrion Company Information
- 8.5.2 Kedrion Business Overview
- 8.5.3 Kedrion Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Kedrion Colloids (Blood Plasma) Product Portfolio
- 8.5.5 Kedrion Recent Developments
- 8.6 Shanghai Raas
- 8.6.1 Shanghai Raas Company Information
- 8.6.2 Shanghai Raas Business Overview
- 8.6.3 Shanghai Raas Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Shanghai Raas Colloids (Blood Plasma) Product Portfolio
- 8.6.5 Shanghai Raas Recent Developments
- 8.7 CTBB
- 8.7.1 CTBB Company Information
- 8.7.2 CTBB Business Overview
- 8.7.3 CTBB Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.7.4 CTBB Colloids (Blood Plasma) Product Portfolio
- 8.7.5 CTBB Recent Developments
- 8.8 Hualan Bio
- 8.8.1 Hualan Bio Company Information
- 8.8.2 Hualan Bio Business Overview
- 8.8.3 Hualan Bio Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Hualan Bio Colloids (Blood Plasma) Product Portfolio
- 8.8.5 Hualan Bio Recent Developments
- 8.9 Rongsheng Pharmaceutical
- 8.9.1 Rongsheng Pharmaceutical Company Information
- 8.9.2 Rongsheng Pharmaceutical Business Overview
- 8.9.3 Rongsheng Pharmaceutical Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Rongsheng Pharmaceutical Colloids (Blood Plasma) Product Portfolio
- 8.9.5 Rongsheng Pharmaceutical Recent Developments
- 8.10 Boya Rongsheng
- 8.10.1 Boya Rongsheng Company Information
- 8.10.2 Boya Rongsheng Business Overview
- 8.10.3 Boya Rongsheng Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Boya Rongsheng Colloids (Blood Plasma) Product Portfolio
- 8.10.5 Boya Rongsheng Recent Developments
- 8.11 B. Braun Medical
- 8.11.1 B. Braun Medical Company Information
- 8.11.2 B. Braun Medical Business Overview
- 8.11.3 B. Braun Medical Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.11.4 B. Braun Medical Colloids (Blood Plasma) Product Portfolio
- 8.11.5 B. Braun Medical Recent Developments
- 8.12 Fresenius Kabi
- 8.12.1 Fresenius Kabi Company Information
- 8.12.2 Fresenius Kabi Business Overview
- 8.12.3 Fresenius Kabi Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.12.4 Fresenius Kabi Colloids (Blood Plasma) Product Portfolio
- 8.12.5 Fresenius Kabi Recent Developments
- 8.13 HOSPIRA
- 8.13.1 HOSPIRA Company Information
- 8.13.2 HOSPIRA Business Overview
- 8.13.3 HOSPIRA Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.13.4 HOSPIRA Colloids (Blood Plasma) Product Portfolio
- 8.13.5 HOSPIRA Recent Developments
- 8.14 Axa parenterals
- 8.14.1 Axa parenterals Company Information
- 8.14.2 Axa parenterals Business Overview
- 8.14.3 Axa parenterals Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.14.4 Axa parenterals Colloids (Blood Plasma) Product Portfolio
- 8.14.5 Axa parenterals Recent Developments
- 8.15 Fresenius Kabi (China)
- 8.15.1 Fresenius Kabi (China) Company Information
- 8.15.2 Fresenius Kabi (China) Business Overview
- 8.15.3 Fresenius Kabi (China) Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.15.4 Fresenius Kabi (China) Colloids (Blood Plasma) Product Portfolio
- 8.15.5 Fresenius Kabi (China) Recent Developments
- 8.16 CR Double-Crane
- 8.16.1 CR Double-Crane Company Information
- 8.16.2 CR Double-Crane Business Overview
- 8.16.3 CR Double-Crane Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.16.4 CR Double-Crane Colloids (Blood Plasma) Product Portfolio
- 8.16.5 CR Double-Crane Recent Developments
- 8.17 Kelun Group
- 8.17.1 Kelun Group Company Information
- 8.17.2 Kelun Group Business Overview
- 8.17.3 Kelun Group Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.17.4 Kelun Group Colloids (Blood Plasma) Product Portfolio
- 8.17.5 Kelun Group Recent Developments
- 8.18 Shandong Qidu Pharmaceutical
- 8.18.1 Shandong Qidu Pharmaceutical Company Information
- 8.18.2 Shandong Qidu Pharmaceutical Business Overview
- 8.18.3 Shandong Qidu Pharmaceutical Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.18.4 Shandong Qidu Pharmaceutical Colloids (Blood Plasma) Product Portfolio
- 8.18.5 Shandong Qidu Pharmaceutical Recent Developments
- 8.19 Shandong Hualu Pharmaceutical
- 8.19.1 Shandong Hualu Pharmaceutical Company Information
- 8.19.2 Shandong Hualu Pharmaceutical Business Overview
- 8.19.3 Shandong Hualu Pharmaceutical Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.19.4 Shandong Hualu Pharmaceutical Colloids (Blood Plasma) Product Portfolio
- 8.19.5 Shandong Hualu Pharmaceutical Recent Developments
- 8.20 Minsheng Pharma
- 8.20.1 Minsheng Pharma Company Information
- 8.20.2 Minsheng Pharma Business Overview
- 8.20.3 Minsheng Pharma Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.20.4 Minsheng Pharma Colloids (Blood Plasma) Product Portfolio
- 8.20.5 Minsheng Pharma Recent Developments
- 8.21 Kanglepharm
- 8.21.1 Kanglepharm Company Information
- 8.21.2 Kanglepharm Business Overview
- 8.21.3 Kanglepharm Colloids (Blood Plasma) Sales, Value and Gross Margin (2021-2026)
- 8.21.4 Kanglepharm Colloids (Blood Plasma) Product Portfolio
- 8.21.5 Kanglepharm Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Colloids (Blood Plasma) Value Chain Analysis
- 9.1.1 Colloids (Blood Plasma) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Colloids (Blood Plasma) Sales Mode & Process
- 9.2 Colloids (Blood Plasma) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Colloids (Blood Plasma) Distributors
- 9.2.3 Colloids (Blood Plasma) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst